ACE-Inhibitors, β-Blockers, Spironolactone: Do We Need Many More Drugs to Treat Chronic Heart Failure?
暂无分享,去创建一个
G. Sinagra | A. Lenarda | A. Perkan | S. Rakar | G. Sabbadini | F. Longaro | G. Lardieri | L. Salvatore
[1] D. Mann,et al. Contemporary Medical Options for Treating Patients With Heart Failure , 2002, Circulation.
[2] R. McKelvie,et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.
[3] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[4] S Capewell,et al. More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.
[5] M. Packer. Current role of beta-adrenergic blockers in the management of chronic heart failure. , 2001, The American journal of medicine.
[6] J D Horowitz. Home-based intervention: the next step in treatment of chronic heart failure? , 2000, European heart journal.
[7] T. LeJemtel,et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.
[8] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[9] A. Coats. Heart Failure 99 -- the MOXCON story. , 1999, International journal of cardiology.
[10] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[11] L. Stevenson. Inotropic therapy for heart failure. , 1998, The New England journal of medicine.
[12] J. Soler‐Soler,et al. Should we still prescribe digoxin in mild-to-moderate heart failure? Is quality of life the issue rather than quantity? , 1998, European heart journal.
[13] A. Michalsen,et al. Preventable causative factors leading to hospital admission with decompensated heart failure , 1998, Heart.
[14] P. Poole‐Wilson,et al. Successes and failures of current treatment of heart failure , 1998, The Lancet.
[15] W. Colucci,et al. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress , 1998, The Lancet.
[16] W. Abraham,et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.
[17] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[18] J. Hampton. Results of clinical trials with diuretics in heart failure. , 1994, British heart journal.
[19] M. Packer. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.